Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2014.06.042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature.
J Oncol Pharm Pract
October 2020
Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Introduction: Ipilimumab is an anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody. Ipilimumab has shown improvement in overall survival in patients with advanced melanoma. Because ipilimumab activates the immune system against the tumor, ipilimumab is associated with adverse events related to immune system activation.
View Article and Find Full Text PDFIpilimumab-associated Sweet syndrome in a melanoma patient.
J Am Acad Dermatol
November 2014
Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA.
Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma.
J Am Acad Dermatol
April 2014
Division of Dermatology, Washington University, St Louis, Missouri. Electronic address:
Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.
Melanoma Res
December 2013
Departments of aHematology and Medical Oncology bPathology, Mount Sinai School of Medicine, New York, New York, USA.
Sweet's syndrome, a neutrophilic dermatosis, is a known paraneoplastic complication occurring with various malignancies. It has been infrequently reported in association with melanoma. Ipilimumab is an antibody against an inhibitory cytotoxic T-lymphocyte-associated antigen 4 receptor on T cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!